Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Cutaneous squamous cell carcinoma (CSCC) is a prevalent cancer with increasing mortality, comparable to melanoma.
• Immunotherapy, specifically anti-PD1 agents, has transformed advanced CSCC treatment but faces challenges with response rates and acquired resistance.
• Understanding resistance mechanisms in both neoplastic cells and the tumor microenvironment is crucial for improving therapeutic outcomes.

Purpose of the Study:

• To review features predicting response to immunotherapy in advanced CSCC.
• To evaluate combination treatments and novel therapeutic agents for CSCC.
• To enhance survival rates for patients with advanced CSCC through improved treatment strategies.

Main Methods:

• Literature review focusing on immunotherapy response predictors in CSCC.
• Analysis of current and emerging combination regimens involving immunotherapy.
• Examination of novel immunotherapeutic agents and direct tumor immunomodulation strategies.

Main Results:

• Approximately 50% of CSCC patients do not respond to current immunotherapy, and resistance can develop over time.
• Research is investigating indirect immune modulation (vaccines, oncolytic viruses) and direct tumor immunogenicity enhancement (radiotherapy, systemic treatments).
• Identifying response predictors is a key area for optimizing immunotherapy efficacy.

Conclusions:

• Combination therapies and novel agents hold potential for improving advanced CSCC treatment.
• Further research into response predictors and combination strategies is essential.
• Enhanced knowledge of immunotherapy response features may significantly improve patient survival in advanced CSCC.